| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_adc90fe75d4454fddb6b7113cd3067d0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1658 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
| filingDate |
2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efc83c86c5d02e7ee9b6965d312a889b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22efccb6ff1bd870043df9b350fe01f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34a925a04882b830b619fc05213f95be |
| publicationDate |
2021-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021110983-A1 |
| titleOfInvention |
Co-amorphous forms of beta-lactoglobulin and a drug substance |
| abstract |
The present invention relates to co-amorphous forms of a drug substance and a protein, more particularly beta-lactoglobulin, wherein the purity of the beta-lactoglobulin is at least 92% (w/w) of the total amount of protein comprised in the co-amorphous form. The present invention also relates to compositions, such as pharmaceutical compositions, comprising the co-amorphous form. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022258625-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023094538-A1 |
| priorityDate |
2019-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |